BRAINTREE, Mass. and WEST WARWICK, R.I., Sept. 16 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that it has signed a comprehensive software agreement with Blood Centers of America, Inc. ("BCA"), a cooperative of community blood centers. The contract provides multiple incentives for BCA-member blood centers to use Haemonetics' suite of innovative blood management software products, including Prelude and Interlude, part of the Haemonetics' integrated Symphony suite of products, as well as eQue(R) automated interview and assessment donor screening system.

"We are delighted with this agreement which provides tangible benefits for current and potential customers," said Janet Conneely, Vice President and General Manager of Haemonetics' Software Solutions Division. "We know that our customers are challenged to improve the donor experience, throughput, cost per collection and overall resource productivity of their blood centers. As the global leader in blood management solutions, we offer a diverse suite of products that includes devices, information technology platforms, and business services for blood collectors. Our software offerings are comprehensive and can help blood centers achieve their objectives."

Charlie Mosher, President and CEO of BCA, commented on the new agreement. "This is a novel agreement for our membership. We know our membership is challenged to find software that will work in their specific environment, and these products are configurable and flexible to meet the needs of our diverse membership. Many of our members are trying to replace multiple legacy systems, so finding products that are integrated and designed to stay current with future regulatory and market changes was important to us."

Details of the agreement will be made available to BCA members on their website. Customers can also contact Kathy Benn at kbenn@haemonetics.com for more information.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

    Contact:
    Julie Fallon
    Tel. (781) 356-9517
    Alt. Tel. (617) 320-2401

SOURCE Haemonetics Corporation